|
Accueil > Actualité
Novo Nordisk: positive data in hemophilia
(CercleFinance.com) - Novo Nordisk reported positive interim results from the FRONTIER3 phase 3 trial in 70 children (aged one to 11 years) with inhibitor and non-inhibitor hemophilia A, at the 18th EAHAD annual congress in Milan.
These data showed that Mim8 was well tolerated and effective in children with hemophilia A with and without inhibitors, with 74.3% of children on once-weekly Mim8 prophylaxis experiencing no treated bleeds. Novo Nordisk expects Mim8 to be submitted to regulatory authorities during 2025. Data from the ongoing phase 3 FRONTIER program will be published at upcoming congresses and in publications in 2025 and 2026. Copyright (c) 2025 CercleFinance.com. All rights reserved. |
12/02/2025 17:00
Neoenl'AMF valide l'OPA simplifiée de Brookfield 12/02/2025 16:51 Safranaccord avec l'indien TEAL pour produire en Inde 12/02/2025 16:37 Walmarten tête du Dow, UBS optimiste avant les résultats 12/02/2025 16:26 J&Jlance un cathéter amélioré, de nouvelle génération 12/02/2025 16:13 Lyftle titre chute après des résultats jugés mitigés 12/02/2025 16:08 Coviviodernier immeuble The Sign inauguré à Milan Tous les articles sociétés |
